Detailed Abstract
[E-poster - Biliary & Pancreas (Biliary Disease/Surgery)]
[EP 169] Survival Benefit of Concurrent Chemo-Radiotherapy for Advanced Survival Benefit of Concurrent Chemo-Radiotherapy for Advanced Ampulla of Vater Cancer
HYUNG IL SEO 1, BYEONG GWAN NOH 1, YOUNG MOK PARK 1, MYUNGHEE YOON 1
1 SURGERY, Pusan National University Hospital, REPUBLIC OF KOREA
Background : Currently, there is no standard adjuvant therapy for patients with resected ampulla of Vater (AoV) cancer. This study aimed to evaluate the effectiveness of adjuvant concurrent chemoradiotherapy (CCRT) in patients with advanced AoV cancer who underwent curative resection.
Methods : This single-centered, retrospective study included 29 patients with advanced AoV cancer who underwent pancreaticoduodenectomy between 2006 and 2018. The impact of CCRT on advanced AoV cancer was analyzed.
Results : The 1-, 3-, and 5-year RFS rates for patients with advanced AoV cancer were 82.8%, 48.3%, and 40.8%, respectively, and the OS rates were 89.7%, 62.1%, and 51.7%, respectively. Lymphovascular invasion (LVI) was found to be a significant risk factor for RFS and OS in patients with advanced AoV cancer, whereas other factors such as age, tumor size, T stage, LN metastasis, perineural invasion, and differentiation were not significantly associated. Patients who received adjuvant CCRT did not show statistically significant differences in RFS and OS compared to non-CCRT patients, although they had a significantly lower average age and a significantly higher platelet-to-lymphocyte ratio (PLR).
Conclusions : Adjuvant CCRT did not improve survival outcomes in patients with advanced AoV cancer. These findings contribute to existing knowledge on the effectiveness of CCRT in this patient population and provide important insights for clinical decision-making.
Methods : This single-centered, retrospective study included 29 patients with advanced AoV cancer who underwent pancreaticoduodenectomy between 2006 and 2018. The impact of CCRT on advanced AoV cancer was analyzed.
Results : The 1-, 3-, and 5-year RFS rates for patients with advanced AoV cancer were 82.8%, 48.3%, and 40.8%, respectively, and the OS rates were 89.7%, 62.1%, and 51.7%, respectively. Lymphovascular invasion (LVI) was found to be a significant risk factor for RFS and OS in patients with advanced AoV cancer, whereas other factors such as age, tumor size, T stage, LN metastasis, perineural invasion, and differentiation were not significantly associated. Patients who received adjuvant CCRT did not show statistically significant differences in RFS and OS compared to non-CCRT patients, although they had a significantly lower average age and a significantly higher platelet-to-lymphocyte ratio (PLR).
Conclusions : Adjuvant CCRT did not improve survival outcomes in patients with advanced AoV cancer. These findings contribute to existing knowledge on the effectiveness of CCRT in this patient population and provide important insights for clinical decision-making.
SESSION
E-poster
E-Session 03/21 ALL DAY